ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A consensus panel convened by the National Institutes of Health in 2005 recommended that qRT-PCR be used in the initial workup of a CML patient to measure BCR-ABL transcript numbers before initiation of treatment, to monitor the response to treatment, and to detect MRD (Hughes et al., 2006).